In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, discusses the future of BPCDN treatment and how a collaborative care model should play a role in this rare disease.
Andrew A. Lane, MD, PhD
Articles by Andrew A. Lane, MD, PhD
In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, offers an overview of pivekimab sunirine and CD123-directed antibody-drug conjugates (ADCs) in the BPDCN pipeline.
The current research frontier in blastic plasmacytoid dendritic cell neoplasm (BPDCN) is moving toward combination triplet therapies. Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, explores the clinical rationale for triplet regimens combining tagraxofusp-erzs (Elzonris), azacitidine (Vidaza), and ventoclax (Venclexta).
In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, outlines monitoring parameters and intervention strategies required for patient safety following treatment with tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
BPDCN breakthroughs: CD123-targeting tagraxofusp and venetoclax-azacitidine combinations boost remissions, limit myelosuppression, and help reach transplant.
Spot BPDCN fast: skin-first clues, CD123/CD4/CD56 triad, mandatory CNS staging, and transplant-focused remission strategy.
Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.